Improved estimation of the distribution of suppressed plasma HIV-1 RNA in men receiving effective antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 4, 2012, Pages 389-392

  Schneider, Michael F ^a   Margolick, Joseph B ^a   Jacobson, Lisa P ^a   Reddy, Susheel ^b   Martinez Maza, Otoniel ^c,d   Muñoz, Alvaro ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bimodal distribution; HAART; HIV 1 RNA; Limit of detection

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VIRUS CONCENTRATION; VIRUS DETECTION; VIRUS LATENCY; VIRUS VIRULENCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 84859740217     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318246bfce     Document Type: Article

References (16)

1. Li X, Chu H, Gallant JE, et al. Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring. J Epidemiol Community Health. 2006;60:811-818. (Pubitemid 44298835)
2. Sizmann D, Glaubitz J, Simon CO, et al. Improved HIV-1 RNA quantitation by COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 using a novel dual-target approach. J Clin Virol. 2010;49:41-46.
3. Glaubitz J, Sizmann D, Simon CO, et al. Accuracy to 2nd International HIV-1 RNA WHO Standard: assessment of three generations of quantitative HIV-1 RNA nucleic acid amplification tests. J Clin Virol. 2011;50: 119-124.
4. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2008;105:3879-3884. (Pubitemid 351723493)
5. Dinoso JB, Kim SY, Siliciano RF, et al. A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin Infect Dis. 2008;47: 102-104. (Pubitemid 351920594)
6. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 2009;106:9403-9408.
7. Amplicor HIV-1 MONITOR™Test, version 1.5 [package insert]. Branchburg, NJ: Roche Molecular Systems, Inc.; 2002.
8. COBAS™ AmpliPrep/COBAS™ TaqMan™ HIV-1 Test, version 2.0 [package insert]. Branchburg, NJ: Roche Molecular Systems, Inc.; 2010.
9. Kaslow RA, Ostrow DG, Detels R, et al. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126:310-318. (Pubitemid 17102758)
10. Dudley J, Jin S, Hoover D, et al. The Multicenter AIDS Cohort Study: retention after 91/2 years. Am J Epidemiol. 1995;142:323-330.
11. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. Department of Health and Human Services. January 10, 2011:1-166. Available at: http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf. Accessed July 1, 2011.
12. Chu H, Moulton LH, Mack WJ, et al. Correlating two continuous variables subject to detection limits in the context of mixture distributions. Appl Statist. 2005;54:831-845. (Pubitemid 41524357)
13. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278:1295-1300. (Pubitemid 27495742)
14. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997;94:13193-13197. (Pubitemid 27518498)
15. Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol. 2006;80:6441-6457. (Pubitemid 43927447)
16. Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007;3:e46.